A Look At Scholar Rock (SRRK) Valuation After Strong Multi Year Shareholder Returns

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

What recent returns say about Scholar Rock Holding (SRRK)

Scholar Rock Holding (SRRK) stock has been relatively mixed in the short term, with a 1 day return of a 1.4% decline and a roughly flat move over the past week, while remaining negative over the past month and past 3 months.

See our latest analysis for Scholar Rock Holding.

At a share price of $46.45, Scholar Rock Holding has seen short term share price weakness but still carries an 8.53% year to date share price return and a very large 3 year total shareholder return of about 7x. This suggests earlier investors have already experienced substantial gains as expectations around its neuromuscular and oncology pipeline have shifted over time.

If you are comparing Scholar Rock Holding with other healthcare and biotech opportunities, it can be useful to see which peers are already attracting attention in AI driven medicine through the 35 healthcare AI stocks

With SRRK trading at $46.45, showing an 8.53% year to date return and a very large 3 year gain, the key question now is whether current prices understate its pipeline potential or if the market is already looking ahead.

Most Popular Narrative: 15.7% Undervalued

Compared with the last close at $46.45, the most widely followed narrative sets a higher fair value of $55.07. This view is built around a detailed earnings and revenue roadmap.

Scholar Rock Holding currently has no revenue. Analysts are forecasting revenue to reach $398.1 million by March 2029.

Analysts are not forecasting that Scholar Rock Holding will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Scholar Rock Holding's profit margin will increase from 0.0% to the average US Biotechs industry of 10.9% in 3 years.

Read the complete narrative.

Want to see what sits behind that jump from zero revenue to a full commercial profile? The narrative places emphasis on compound revenue growth, shifting margins and a premium earnings multiple that is usually reserved for faster maturing sectors. Curious how these moving parts combine into a higher fair value than today’s price? The full story joins those assumptions into one tight valuation case.

Result: Fair Value of $55.07 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on smooth apitegromab approvals and launch uptake, as well as on the multi asset neuromuscular pipeline avoiding trial setbacks or weaker than expected labels.

Story Continues

Find out about the key risks to this Scholar Rock Holding narrative.

Another way to look at value

The narrative points to a fair value of $55.07, yet Simply Wall St’s DCF model suggests a future cash flow value of $157.25, with SRRK trading at $46.45. Both models flag the stock as undervalued, but the size of the gap raises a simple question: which set of assumptions do you trust more?

Look into how the SWS DCF model arrives at its fair value.SRRK Discounted Cash Flow as at May 2026

Next Steps

The mix of strong past returns and clear uncertainty around approvals and cash flows makes sentiment anything but straightforward. Move quickly to check the data, weigh the upside against the risks, and see how your view compares with the 3 key rewards and 4 important warning signs

Looking for more investment ideas?

If SRRK has caught your attention, do not stop here. Broaden your watchlist with other focused stock ideas so you are not relying on a single bet.

Spot potential bargains early by scanning companies that combine quality and attractive pricing through the 51 high quality undervalued stocks Prioritise resilience by reviewing companies that show lower overall risk profiles using the 72 resilient stocks with low risk scores Hunt for off the radar opportunities by checking the screener containing 23 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SRRK.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments